The β-arrestin1/endothelin axis bolsters ovarian fibroblast-dependent invadosome activity and cancer cell metastatic potential.
Humans
Female
Ovarian Neoplasms
/ metabolism
beta-Arrestin 1
/ metabolism
Cancer-Associated Fibroblasts
/ metabolism
Cell Line, Tumor
Podosomes
/ metabolism
Endothelin-1
/ metabolism
Neoplasm Metastasis
Receptor, Endothelin A
/ metabolism
Signal Transduction
Extracellular Matrix
/ metabolism
Cell Movement
Cell Proliferation
Animals
Fibroblasts
/ metabolism
Neoplasm Invasiveness
Journal
Cell death & disease
ISSN: 2041-4889
Titre abrégé: Cell Death Dis
Pays: England
ID NLM: 101524092
Informations de publication
Date de publication:
22 May 2024
22 May 2024
Historique:
received:
17
10
2023
accepted:
08
05
2024
revised:
06
05
2024
medline:
23
5
2024
pubmed:
23
5
2024
entrez:
22
5
2024
Statut:
epublish
Résumé
Recruitment of fibroblasts to tumors and their activation into cancer-associated fibroblasts (CAFs) is a strategy used by tumor cells to direct extracellular matrix (ECM) remodeling, invasion, and metastasis, highlighting the need to investigate the molecular mechanisms driving CAF function. Endothelin-1 (ET-1) regulates the communication between cancer and stroma and facilitates the progression of serous ovarian cancer (SOC). By binding to Endothelin A (ET
Identifiants
pubmed: 38777849
doi: 10.1038/s41419-024-06730-6
pii: 10.1038/s41419-024-06730-6
doi:
Substances chimiques
beta-Arrestin 1
0
Endothelin-1
0
Receptor, Endothelin A
0
ARRB1 protein, human
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
358Subventions
Organisme : Associazione Italiana per la Ricerca sul Cancro (Italian Association for Cancer Research)
ID : 21372
Informations de copyright
© 2024. The Author(s).
Références
Dasari S, Fang Y, Mitra AK. Cancer associated fibroblasts: naughty neighbors that drive ovarian cancer progression. Cancers. 2018;10:406.
pubmed: 30380628
pmcid: 6265896
doi: 10.3390/cancers10110406
Ding H, Zhang J, Zhang F, Xu Y, Yu Y, Liang W, et al. Role of cancer-associated fibroblast in the pathogenesis of ovarian Cancer: Focus on the latest therapeutic approaches. Int Immunopharmacol. 2022;110:109052.
pubmed: 35978506
doi: 10.1016/j.intimp.2022.109052
Naik A, Leask A. Tumor-associated fibrosis impairs the response to immunotherapy. Matrix Biol. 2023;119:125–40.
pubmed: 37080324
doi: 10.1016/j.matbio.2023.04.002
Yeung TL, Leung CS, Yip KP, Au Yeung CL, Wong ST, Mok SC. Cellular and molecular processes in ovarian cancer metastasis. a review in the theme: cell and molecular processes in cancer metastasis. Am J Physiol Cell Physiol. 2015;309:C444–56.
pubmed: 26224579
pmcid: 4593771
doi: 10.1152/ajpcell.00188.2015
Lengyel E. Ovarian cancer development and metastasis. Am J Pathol. 2010;177:1053–64.
pubmed: 20651229
pmcid: 2928939
doi: 10.2353/ajpath.2010.100105
Brown Y, Hua S, Tanwar PS. Extracellular matrix in high-grade serous ovarian cancer: advances in understanding of carcinogenesis and cancer biology. Matrix Biol. 2023;118:16–46.
pubmed: 36781087
doi: 10.1016/j.matbio.2023.02.004
Govindarajan M, Ignatchenko V, Ailles L, Kislinger T. Proteomics of high-grade serous ovarian cancer models identifies cancer-associated fibroblast markers associated with clinical outcomes. Biomolecules. 2022;13:75.
pubmed: 36671461
pmcid: 9855416
doi: 10.3390/biom13010075
Xu J, Fang Y, Chen K, Li S, Tang S, Ren Y, et al. Single-cell RNA sequencing reveals the tissue architecture in human high-grade serous ovarian cancer. Clin Cancer Res. 2022;28:3590–602.
pubmed: 35675036
pmcid: 9662915
doi: 10.1158/1078-0432.CCR-22-0296
Ferri-Borgogno S, Zhu Y, Sheng J, Burks JK, Gomez JA, Wong KK, et al. Spatial transcriptomics depict ligand-receptor crosstalk heterogeneity at the tumor-stroma interface in long-term ovarian cancer survivors. Cancer Res. 2023;83:1503–16.
pubmed: 36787106
pmcid: 10159916
doi: 10.1158/0008-5472.CAN-22-1821
Deng Y, Tan Y, Zhou D, Bai Y, Cao T, Zhong C, et al. Single-Cell RNA-sequencing atlas reveals the tumor microenvironment of metastatic high-grade serous ovarian carcinoma. Front Immunol. 2022;13:923194.
pubmed: 35935940
pmcid: 9354882
doi: 10.3389/fimmu.2022.923194
Carvalho RF, do Canto LM, Abildgaard C, Aagaard MM, Tronhjem MS, Waldstrom M, et al. Single-cell and bulk RNA sequencing reveal ligands and receptors associated with worse overall survival in serous ovarian cancer. Cell Commun Signal. 2022;20:176.
pubmed: 36352420
pmcid: 9648056
doi: 10.1186/s12964-022-00991-4
Zhao Y, Mei S, Huang Y, Chen J, Zhang X, Zhang P. Integrative analysis deciphers the heterogeneity of cancer-associated fibroblast and implications on clinical outcomes in ovarian cancers. Comput Struct Biotechnol J. 2022;20:6403–11.
pubmed: 36420154
pmcid: 9679440
doi: 10.1016/j.csbj.2022.11.025
Gertych A, Walts AE, Cheng K, Liu M, John J, Lester J, et al. Dynamic changes in the extracellular matrix in primary, metastatic, and recurrent ovarian cancers. Cells. 2022;11:3769.
pubmed: 36497028
pmcid: 9736731
doi: 10.3390/cells11233769
Gao Q, Yang Z, Xu S, Li X, Yang X, Jin P, et al. Heterotypic CAF-tumor spheroids promote early peritoneal metastatis of ovarian cancer. J Exp Med. 2019;216:688–703.
pubmed: 30710055
pmcid: 6400537
doi: 10.1084/jem.20180765
Chen X, Song E. Turning foes to friends: targeting cancer-associated fibroblasts. Nat Rev Drug Discov. 2019;18:99–115.
pubmed: 30470818
doi: 10.1038/s41573-018-0004-1
Chen Y, McAndrews KM, Kalluri R. Clinical and therapeutic relevance of cancer-associated fibroblasts. Nat Rev Clin Oncol. 2021;18:792–804.
pubmed: 34489603
pmcid: 8791784
doi: 10.1038/s41571-021-00546-5
Lebel M, Cliche DO, Charbonneau M, Adam D, Brochiero E, Dubois CM, et al. Invadosome formation by lung fibroblasts in idiopathic pulmonary fibrosis. Int J Mol Sci. 2022;24:499.
pubmed: 36613948
pmcid: 9820272
doi: 10.3390/ijms24010499
Gulvady AC, Forsythe IJ, Turner CE. Hic-5 regulates Src-induced invadopodia rosette formation and organization. Mol Biol Cell. 2019;30:1298–313.
pubmed: 30893012
pmcid: 6724605
doi: 10.1091/mbc.E18-10-0629
Chen YW, Lai CS, Chen YF, Chiu WT, Chen HC, Shen MR. STIM1-dependent Ca(2+) signaling regulates podosome formation to facilitate cancer cell invasion. Sci Rep. 2017;7:11523.
pubmed: 28912430
pmcid: 5599537
doi: 10.1038/s41598-017-11273-2
Rafiq NB, Lieu ZZ, Jiang T, Yu CH, Matsudaira P, Jones GE, et al. Podosome assembly is controlled by the GTPase ARF1 and its nucleotide exchange factor ARNO. J Cell Biol. 2017;216:181–97.
pubmed: 28007915
pmcid: 5223603
doi: 10.1083/jcb.201605104
Goicoechea SM, Garcia-Mata R, Staub J, Valdivia A, Sharek L, McCulloch CG, et al. Palladin promotes invasion of pancreatic cancer cells by enhancing invadopodia formation in cancer-associated fibroblasts. Oncogene. 2014;33:1265–73.
pubmed: 23524582
doi: 10.1038/onc.2013.68
Maharana J, Banerjee R, Yadav MK, Sarma P, Shukla AK. Emerging structural insights into GPCR-beta-arrestin interaction and functional outcomes. Curr Opin Struct Biol. 2022;75:102406.
pubmed: 35738165
pmcid: 7614528
doi: 10.1016/j.sbi.2022.102406
Bagnato A, Rosano L. New routes in GPCR/beta-arrestin-driven signaling in cancer progression and metastasis. Front Pharmacol. 2019;10:114.
pubmed: 30837880
pmcid: 6390811
doi: 10.3389/fphar.2019.00114
Del Rio D, Masi I, Caprara V, Spadaro F, Ottavi F, Strippoli R, et al. Ovarian cancer-driven mesothelial-to-mesenchymal transition is triggered by the endothelin-1/beta-arr1 axis. Front Cell Dev Biol. 2021;9:764375.
pubmed: 34926453
pmcid: 8672058
doi: 10.3389/fcell.2021.764375
Rosano L, Spinella F, Bagnato A. Endothelin 1 in cancer: biological implications and therapeutic opportunities. Nat Rev Cancer. 2013;13:637–51.
pubmed: 23884378
doi: 10.1038/nrc3546
Weigert A, Zheng X, Nenzel A, Turkowski K, Gunther S, Strack E, et al. Fibrocytes boost tumor-supportive phenotypic switches in the lung cancer niche via the endothelin system. Nat Commun. 2022;13:6078.
pubmed: 36241617
pmcid: 9568595
doi: 10.1038/s41467-022-33458-8
Son S, Shin JM, Shin S, Kim CH, Lee JA, Ko H, et al. Repurposing macitentan with nanoparticle modulates tumor microenvironment to potentiate immune checkpoint blockade. Biomaterials. 2021;276:121058.
pubmed: 34399119
doi: 10.1016/j.biomaterials.2021.121058
Haque SU, Dashwood MR, Heetun M, Shiwen X, Farooqui N, Ramesh B, et al. Efficacy of the specific endothelin a receptor antagonist zibotentan (ZD4054) in colorectal cancer: a preclinical study. Mol Cancer Ther. 2013;12:1556–67.
pubmed: 23723122
doi: 10.1158/1535-7163.MCT-12-0975
Masi I, Caprara V, Spadaro F, Chellini L, Sestito R, Zancla A, et al. Endothelin-1 drives invadopodia and interaction with mesothelial cells through ILK. Cell Rep. 2021;34:108800.
pubmed: 33657382
doi: 10.1016/j.celrep.2021.108800
Masi I, Ottavi F, Del Rio D, Caprara V, Vastarelli C, Giannitelli SM, et al. The interaction of beta-arrestin1 with talin1 driven by endothelin A receptor as a feature of alpha5beta1 integrin activation in high-grade serous ovarian cancer. Cell Death Dis. 2023;14:73.
pubmed: 36717550
pmcid: 9886921
doi: 10.1038/s41419-023-05612-7
Suvarna K, Honda K, Kondoh Y, Osada H, Watanabe N. Identification of a small-molecule ligand of beta-arrestin1 as an inhibitor of stromal fibroblast cell migration accelerated by cancer cells. Cancer Med. 2018;7:883–93.
pubmed: 29380537
pmcid: 5852355
doi: 10.1002/cam4.1339
Tocci P, Roman C, Sestito R, Di Castro V, Sacconi A, Molineris I, et al. Targeting tumor-stroma communication by blocking endothelin-1 receptors sensitizes high-grade serous ovarian cancer to PARP inhibition. Cell Death Dis. 2023;14:5.
pubmed: 36604418
pmcid: 9816119
doi: 10.1038/s41419-022-05538-6
Weber K, Hey S, Cervero P, Linder S. The circle of life: phases of podosome formation, turnover and reemergence. Eur J Cell Biol. 2022;101:151218.
pubmed: 35334303
doi: 10.1016/j.ejcb.2022.151218
Di Modugno F, Caprara V, Chellini L, Tocci P, Spadaro F, Ferrandina G, et al. hMENA is a key regulator in endothelin-1/beta-arrestin1-induced invadopodial function and metastatic process. Proc Natl Acad Sci USA. 2018;115:3132–7.
pubmed: 29439204
pmcid: 5866561
doi: 10.1073/pnas.1715998115
Chellini L, Caprara V, Spadaro F, Sestito R, Bagnato A, Rosano L. Regulation of extracellular matrix degradation and metastatic spread by IQGAP1 through endothelin-1 receptor signalling in ovarian cancer. Matrix Biol. 2019;81:17–33.
pubmed: 30367951
doi: 10.1016/j.matbio.2018.10.005
Semprucci E, Tocci P, Cianfrocca R, Sestito R, Caprara V, Veglione M, et al. Endothelin A receptor drives invadopodia function and cell motility through the beta-arrestin/PDZ-RhoGEF pathway in ovarian carcinoma. Oncogene. 2016;35:3432–42.
pubmed: 26522724
doi: 10.1038/onc.2015.403
Han Q, Huang B, Huang Z, Cai J, Gong L, Zhang Y, et al. Tumor cell‑fibroblast heterotypic aggregates in malignant ascites of patients with ovarian cancer. Int J Mol Med. 2019;44:2245–55.
pubmed: 31638162
pmcid: 6844628
Caligiuri G, Tuveson DA. Activated fibroblasts in cancer: perspectives and challenges. Cancer Cell. 2023;41:434–49.
pubmed: 36917949
pmcid: 11022589
doi: 10.1016/j.ccell.2023.02.015
Simon T, Salhia B. Cancer-associated fibroblast subpopulations with diverse and dynamic roles in the tumor microenvironment. Mol Cancer Res. 2022;20:183–92.
pubmed: 34670861
pmcid: 9306405
doi: 10.1158/1541-7786.MCR-21-0282
Knowles JP, Shi-Wen X, Haque SU, Bhalla A, Dashwood MR, Yang S, et al. Endothelin-1 stimulates colon cancer adjacent fibroblasts. Int J Cancer. 2012;130:1264–72.
pubmed: 21445967
doi: 10.1002/ijc.26090
Lavie D, Ben-Shmuel A, Erez N, Scherz-Shouval R. Cancer-associated fibroblasts in the single-cell era. Nat Cancer. 2022;3:793–807.
pubmed: 35883004
pmcid: 7613625
doi: 10.1038/s43018-022-00411-z
Givel AM, Kieffer Y, Scholer-Dahirel A, Sirven P, Cardon M, Pelon F, et al. miR200-regulated CXCL12beta promotes fibroblast heterogeneity and immunosuppression in ovarian cancers. Nat Commun. 2018;9:1056.
pubmed: 29535360
pmcid: 5849633
doi: 10.1038/s41467-018-03348-z
Zou R, Jiang Q, Jin T, Chen M, Yao L, Ding H. Pan-cancer analyses and molecular subtypes based on the cancer-associated fibroblast landscape and tumor microenvironment infiltration characterization reveal clinical outcome and immunotherapy response in epithelial ovarian cancer. Front Immunol. 2022;13:956224.
pubmed: 36032075
pmcid: 9402225
doi: 10.3389/fimmu.2022.956224
Cao H, Eppinga RD, Razidlo GL, Krueger EW, Chen J, Qiang L, et al. Stromal fibroblasts facilitate cancer cell invasion by a novel invadopodia-independent matrix degradation process. Oncogene. 2016;35:1099–110.
pubmed: 25982272
doi: 10.1038/onc.2015.163
Cannone S, Greco MR, Carvalho TMA, Guizouarn H, Soriani O, Di Molfetta D, et al. Cancer associated fibroblast (CAF) regulation of PDAC parenchymal (CPC) and CSC phenotypes is modulated by ECM composition. Cancers. 2022;14:3737.
pubmed: 35954400
pmcid: 9367491
doi: 10.3390/cancers14153737
Ezzoukhry Z, Henriet E, Cordelieres FP, Dupuy JW, Maitre M, Gay N, et al. Combining laser capture microdissection and proteomics reveals an active translation machinery controlling invadosome formation. Nat Commun. 2018;9:2031.
pubmed: 29795195
pmcid: 5966458
doi: 10.1038/s41467-018-04461-9
Kato K, Miyazawa H, Kawashiri S, Lambert DW. Tumour: fibroblast interactions promote invadopodia-mediated migration and invasion in oral squamous cell carcinoma. J Oncol. 2022;2022:5277440.
pubmed: 36471888
pmcid: 9719419
doi: 10.1155/2022/5277440
Yang D, Liu J, Qian H, Zhuang Q. Cancer-associated fibroblasts: from basic science to anticancer therapy. Exp Mol Med. 2023;55:1322–32.
pubmed: 37394578
pmcid: 10394065
doi: 10.1038/s12276-023-01013-0
Diaz B. Invadopodia detection and gelatin degradation assay. Bio Protoc. 2013;3:e997.
pubmed: 30443559